Singapore Institute of Advanced Medicine Holdings Ltd. – Major Corporate Updates: Rights cum Warrants Issue & Loan Conversion

Key Points from the Latest Announcement

• Renounceable Non-Underwritten Rights cum Warrants Issue: The company is proceeding with a significant fund-raising exercise, offering up to 492,597,856 new Rights Shares and the same number of free detachable Warrants. The Rights Issue will be conducted at an issue price of S\$0.031 per Rights Share, with each Rights Share accompanied by one free Warrant, exercisable at S\$0.050 per Warrant.
• Conversion of Shareholder Loans: Espeetex Sdn. Bhd.’s shareholder loans are proposed to be converted into new shares, pending regulatory approval and a whitewash waiver from the Securities Industry Council (SIC).
• No Need for EGM Approval: As the Rights cum Warrants Issue is within the approved general share issuance mandate, no extraordinary general meeting (EGM) will be convened for this transaction.

Detailed Insights for Investors

1. Rights cum Warrants Issue Structure and Rationale

• The Rights Issue will be conducted on a pro rata basis to existing shareholders, with a maximum of 492,597,856 Rights Shares to be issued, each with a free detachable Warrant. This falls within the general share issuance mandate approved at the 2025 AGM, which allows up to 1,231,494,642 new shares to be issued.
• The Rights Shares will be issued at S\$0.031, representing a steep discount (36.73%) to the last traded price of S\$0.049 on 22 April 2026. This is a deeper discount compared to the 16.22% discount as at the initial October 2025 announcement, making the offer more attractive to investors. The theoretical ex-rights price (TERP) is S\$0.044, meaning Rights Shares are also offered at a 29.32% discount to TERP.
• The Warrants are exercisable at S\$0.050, a 2.04% premium to the last traded price, and a 14.01% premium to the TERP. If fully exercised, the company could raise an additional S\$24.63 million.

2. Irrevocable Undertakings from Major Shareholders

• Several major shareholders (including Berjaya Group entities, Caterine Limited, Crescendas Land Corporation, Dr Djeng Shih Kien, and PHEIM group) have furnished irrevocable undertakings to subscribe for their full pro rata entitlements. Some have also committed to take up excess unsubscribed Rights, ensuring that at least S\$14.9 million (the minimum required for the company’s 12-month working capital) will be raised.
• Prepayments of S\$3.9 million have already been received from certain undertaking shareholders, providing immediate liquidity and underlining the confidence of key stakeholders.

3. Shareholding Scenarios Post-Issue

• Upon completion, the company’s share base could increase from 1,231,494,642 to 1,724,092,498 shares (excluding warrant exercise), or to 2,216,690,354 shares if all warrants are exercised.
• In both maximum and minimum subscription scenarios, major shareholders will maintain significant stakes, with Berjaya Group entities, Caterine Limited, Crescendas Land Corporation, Dr Djeng, and PHEIM collectively accounting for the majority of shares post-issue.

4. Financial Condition and Going Concern Risks

• The company’s auditors, Foo Kon Tan LLP, have issued a disclaimer of opinion on the FY2025 accounts, citing inability to obtain sufficient audit evidence on certain balances, uncertainties on going concern, and issues relating to asset recoverability and impairment.
• For FY2025 and the half-year ended 31 December 2025, the company reported losses of S\$27 million and S\$11.6 million respectively. As of end-2025, current liabilities exceeded current assets by S\$16.9 million, with cash reserves at S\$3.85 million.
• The outcome of the Rights Issue is critical to the company’s ongoing viability. If the minimum required amount is not raised, the company will seek alternative funding or risk suspension of its shares and potential non-viability as a going concern.

5. Use of Proceeds

• Net proceeds of S\$14.94 million will be allocated primarily to working capital (71.2%), system maintenance and software upgrades (25.4%), and system revamp/capital expenditure (3.4%).
• Earlier plans to repay short-term bridging loans have been revised as prepayments from shareholders have already been used for payroll and maintenance expenses.
• If all warrants are exercised, the company could receive an additional S\$24.63 million, with no change in the previously announced use of these proceeds.

6. Shareholder Actions and Next Steps

• No EGM will be convened for the Rights Issue, but an Offer Information Statement will be issued to set out the full terms and conditions.
• The company will seek a whitewash waiver from the SIC in connection with the Espeetex loan conversion to avoid triggering a mandatory offer. Shareholder approval will be sought for this separately if the waiver is granted.

Potential Price-Sensitive Information

• Deep Discounted Rights Issue: The Rights Shares are offered at a substantial discount to market prices, which could impact secondary market pricing and attract significant trading interest.
• Auditor’s Disclaimer of Opinion: The disclaimer flags material uncertainties over going concern and asset values, which could severely affect investor sentiment and share valuation.
• Going Concern Risks: The company’s continued operation hinges on the success of this fund-raising. Failure to raise the minimum required funds could result in trading suspension or more severe outcomes.
• Major Shareholder Support: The strong undertakings and substantial prepayments from cornerstone investors provide some assurance but also highlight the company’s reliance on a narrow shareholder base.

Conclusion

This corporate update is highly material for investors. The deep-discounted Rights Issue, coupled with the company’s auditor disclaimer and going concern risks, presents both significant risk and a potential opportunity depending on the company’s ability to execute its plans and restore financial stability. Shareholders and potential investors should closely monitor developments around the Rights Issue, the company’s financial performance, and the upcoming Offer Information Statement for further details.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence, consult their financial advisers, and review official company statements and regulatory filings before making any investment decisions. The author and publisher assume no liability for investment losses or other damages arising from the use of this information.

View SAM Holdings Historical chart here